

Version with Markings to show Changes Made according to (37 CFR 1.121)

2. [The use of] C[c]ompounds [of formula I as claimed in] according to claim 1, wherein A is-O-.
3. [The use of] C[c]ompounds [of formula I as claimed in] according to [any preceding claim] according to claim 1, wherein B is-O-.
4. [The use of] C[c]ompounds [of formula I as claimed in any preceding claim] according to claim 1, wherein g is 0, 1 or 2.
5. [The use of] C[c]ompounds [of formula I as claimed in any preceding claim] according to claim 1, wherein R₁ represents halo, an alkyl group containing 1 to 3 carbon atoms, an alkoxy group containing 1 to 3 carbon atoms, hydroxy, or two adjacent R₁ groups together with the carbon atoms to which they are attached forming a fused benzene ring.
6. [The use of] C[c]ompounds [of formula I as claimed in any preceding claim] according to claim 1, wherein R₁ represents methoxy, fluoro, chloro, hydroxy, or two adjacent R₁ groups together with the carbon atoms to which they are attached forming a fused benzene ring.
7. [The use of] C[c]ompounds [of formula I as claimed in any preceding claim] according to claim 1, wherein R₂ is H or an alkyl group containing 1 to 3 carbon atoms.
8. [The use of] C[c]ompounds [of formula I as claimed in any preceding claim] according to claim 1, wherein R3 and R4, which are the same or different, are H or methyl.
9. [The use of] C[c]ompounds [of formula I as claimed in any preceding claim] according to claim 1, wherein T is pyridyl, pyrimidinyl, pyrazinyl, phenyl,

benzofuryl, 1,4-benzodioxanyl or quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo.

10. [The use of] C[c]ompounds [of formula I as claimed in any preceding claim] according to claim 1, wherein T is 2-pyridyl, 2-pyrimidinyl, 2-pyrazinyl, phenyl, 2,3-dihydrobenzo [b] furan-7 yl, 1,4-benzodioxan-5-yl or 4-quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo.

11. [The use of] C[c]ompounds [of formula I as claimed in any preceding claim] according to claim 1, wherein R5 is H or methyl.

12. [The use of] C[c]ompounds [of formula I as claimed in any preceding claim] according to claim 1, which are:

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrazin-2-yl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (3-chloropyrid-2-yl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (quinazolin-4-yl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrid-2-yl) piperid-4-yl] methylamine;

N- (8-Methoxy-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-N'- [3- (trifluoromethyl)-2-pyridyl] ethanediamine;

N- (8-Methoxy-1, 2, 3, 4-tetrahydronaphth-2-ylmethyl)-1- [1-pyrimidin-2-yl] piperid-4- yl] methylamine;

7- {B-[1-(Pyrimidin-2-yl) piperid-4-ylmethyl] aminomethyl}-5,{B-[1-(Pyrimidin-2-yl) piperid-4-ylmethyl] aminomethyl}-5, 6,7,8-tetrahydronaphth-1ol;

N- (5-Methoxy-3, 4-dihydro-2H-1-benzopyran-3-ylmethyl)-1- [1-(pyrimidin-2-yl) piperid 4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- (1-phenylpiperid-4-yl) methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (1, 4-benzodioxan-5-yl) piperid-4yl] methylamine;

1- [1- (1, 4-Benzodioxan-2-ylmethyl) piperid-4-yl]-N- (2-methoxyphenyl) methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (4-methoxyphenyl) piperid-4-yl] methylamine;

N- (8-Methoxy-1, 4-benzodioxan-2-ylmethyl)-N- (2-methoxyphenyl)-1,3-propanediamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (3-methoxyphenyl) piperid-4-yl] methylamine;

N- (6, 7-Dichloro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-chlorophenyl) piperid-4-yl] methylamine;

N- (5-Fluoro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (8-Fluoro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

1-[1- (2-methoxyphenyl) piperid-4-yl]-N- (naphtho [1,2-b] dioxan-2ylmethyl) methylamine;

1- [1- (2, 3-Dihydrobenzo [b] furan-7-yl) piperid-4-yl]-N- (8-methoxy-1, 4-benzodioxan-2- ylmethyl) methylamine;

N- (6-Chloro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (7-Chloro-1, 4-benzodioxan-2-ylmethyl)-1- (1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (8-hydroxy-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine; and or

pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers.

13. [The use of] C[c]ompounds [of formula I as claimed in] according to claim 12, which are:


(S)- (-)-N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

(R)- (+)-N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

(-)N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrid-2-yl) piperid-4-yl] methylamine dihydrochloride; or

(+)-N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrid-2-yl) piperid-4-yl] methylamine dihydrochloride.

14. [The use of] A method for reducing cravings to food or an addictive substance, comprising: administering a therapeutically effective amount of a compound[s] of formula I



[and] or pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers, in which:

A is 0-;

Bis-0-;


g is 0 or 1;

R₁ represents halo, an alkyl group containing 1 to 3 carbon atoms, an alkoxy group containing 1 to 3 carbon atoms, or hydroxy;


R₂, R₃ and R₄ are each H;

U is methylene;

Q is [a group of formula] IIa



or IIc



in which V is methylene or ethylene; X is an alkylene chain containing 0 to 2 carbon atoms and X' is an alkylene chain containing 1 to 4 carbon atoms provided that the total number of carbon atoms in X and X' amounts to 3 or 4; and R₅ is H; and T is pyridyl, pyrazinyl, phenyl, benzo [b] furanyl, 1,4-benzodioxanyl, or quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo[; for use in reducing cravings to food or an addictive substance].

16. [The use of compounds of formula I as claimed in] A method according to claim 14, wherein T is 2pyridyl, 2-pyrazinyl, phenyl, 2,3-dihydrobenzoLb] furan-7-yl, 1,4-benzodioxan-5-yl or 4quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo.

17. [The use of compounds of formula I as claimed in] A method according to claim 14, wherein the compounds of formula 1 are selected from:

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrazin-2-yl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (3-chloropyrid-2-yl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (quinazolin-4-yl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrid-2-yl) piperid-4-yl] methylamine;

N- (8-Methoxy-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- (1-phenylpiperid-4-yl) methylamine;
N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (1, 4-benzodioxan-5-yl) piperid-4yl] methylamine;

1- [1- (1, 4-Benzodioxan-2-ylmethyl) piperid-4-yl]-N- (2-methoxyphenyl) methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (4-methoxyphenyl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (3-methoxyphenyl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-chlorophenyl) piperid-4-yl] methylamine;

N- (5-Fluoro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (8-Fluoro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

1- [1- (2, 3-Dihydrobenzo [b] furan-7-yl) piperid-4-yl]-N- (8-methoxy-1,4-benzodioxan-2- ylmethyl) methylamine;

N- (6-Chloro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine ;

N- (7-Chloro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (8-hydroxy-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine; and

pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers.

18. [The use of compounds of formula I as claimed in] A method according to claim 14 wherein the compounds of formula 1 are selected from: [which are:]
- (S)- (-)-N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4- yl] methylamine;
- (R)- (+)-N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;
- (-)N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrid-2-yl) piperid-4-yl] methylamine dihydrochloride ; and
- (+)-N-(1, 4-Benzodioxan-2-ylmethyl)-1-[1-(pyrid-2-yl) piperid-4-yl] methylamine dihydrochloride.

19. [The compound of formula I as claimed in] A method according to claim 14 wherein the compounds of formula 1 are selected from: [which is:]
- N- (7-Chloro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl]methylamine; and

pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers.

20. A method for reducing cravings to food or an addictive substance, [The use of pharmaceutical compositions] comprising: administering a therapeutically effective amount of a compound of formula 1, together with a pharmaceutically acceptable diluent or carrier in reducing cravings to food or an addictive substance.